课题基金 / 基金详情

Functional analysis of the molecules modulating the proliferative signals of human myeloma cells by IL-6

Functional analysis of the molecules modulating the proliferative signals of human myeloma cells by IL-6
IL-6调节人骨髓瘤细胞增殖信号分子的功能分析
批准号:
12670991
负责人:
ISHIKAWA Hideaki
金额:
$2.11万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2001

项目摘要

项目成果

ISHIKAWA Hideaki的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Interleukin-6 (IL-6) has a variety of biological functions in different cells and is a growth factor for human myeloma cells. IL-6 receptor complexes consist of the IL-6 receptor a chain (IL-6Rα) and gp130, the latter being commonly used as a signal-transducing molecule by the members of the IL-6 family of cytokines. Specific intracellular signals mediated by IL-6 receptor complexes, such as signal transducers and activators of transcription 3 (STAT3) and extracellular signal-regulated kinase (ERK) 1/2, are considered to be responsible for inducing a variety of cellular responses. CD45 antigens are initially characterized as leukocyte common antigen expressed on all hematopoietic cells except for mature erythrocytes and platelets. Dephosphorylation of the COOH-terminal tyrosine residue of src family kinases by CD45 phosphatase has been implicated a mechanism of src family kinase activation. The activated src family kinases mediate downstream the signals of several extracellular stimuli … More , such as growth factors, cytokines, and antigen stimulation, leading to diversification and amplification of the initial signals. Although the roles of CD45 have been extensively studied for antigen receptors in B and T cells, its physiological consequences in other hematopoietic cells remain largely unknown. We recently found that myeloma cells expressing CD45 form a proliferating population in multiple myeloma (MM). Thus, MM seems a good example in which to address the biological functions of CD45 molecules in cell proliferation promoted by the cytokine, IL-6. In MM, IL-6 only enhanced the proliferation of CD45^+ tumor cells that harbored the IL-6-independent activation of src family kinases even though STAT3 and ERK1/2 could be activated in response to IL-6 in both CD45^+ and CD45^- cells. Furthermore, the IL-6-induced proliferation of CD45^+ U266 myeloma cells was significantly suppressed by Lyn-specific antisense oligodeoxynucleotides or a selective src kinase inhibitor. These results indicates that the activation of both STATS and ERK1/2 is not sufficient for IL-6-induced proliferation of myeloma cell lines that require src family kinase activation independent of IL-6 stimulation. Thus, the activation of the src family kinases associated with CD45 expression is a prerequisite for the proliferation of myeloma cell lines by IL-6. We propose a mechanism for IL-6-induced cell proliferation that is strictly dependent upon the cellular context in myeloma.This is also supported by another finding that KMS11 expressing fibroblast growth factor receptor (FGFR) 3 proliferated in response to IL-6 together with FGF. IL-6 or FGF alone failed to enhance the proliferation of KMS11 myeloma cell line. FGF could activated several signaling molecules different from those by IL-6, and both together finally induce the proliferative signals in KMS11 that does not express CD45. Less
期刊论文(21)
专著(0)
科研奖励(0)
会议论文
Ishikawa, H.: "CD19 expression and growth inhibition of tumors in human multiple myeloma"Leuk. Lymphoma. (in press). (2002)
Ishikawa, H.:“人多发性骨髓瘤中 CD19 的表达和肿瘤生长抑制”Leuk。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Ishikawa, H.: "CD19 expression and growth inhibition of tumors in human multiple myeloma."Leuk. Lymphoma. (in press). (2002)
Ishikawa, H.:“人类多发性骨髓瘤中的 CD19 表达和肿瘤生长抑制。”Leuk。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Ishikawa,H.: "Pax-5 genes and CD19 molecules in human myeloma"Jpn. J. Clin. Hematol. 41 (5). 404-407 (2000)
Ishikawa,H.:“人类骨髓瘤中的 Pax-5 基因和 CD19 分子”Jpn。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Ishikawa,H.: "Pax-5 and plasmacytoid lymphoma"Hematol, Frontier. 10 (9). 1185-1192 (2000)
Ishikawa,H.:“Pax-5 和浆细胞样淋巴瘤”Hematol,Frontier。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
20
    Development and the utilization of the social science education unification program to promote new combination of the knowledge
    • 批准号:
      24650534
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $1.33万
    • 财政年份:
      2012
    • 负责人:
      ISHIKAWA Hideaki
    • 依托单位:
    The Role of the Lyn-PI 3-kinase signaling pathways and PKM2 in the myeloma cell proliferation
    The origin of analytic properties of zeta functions on the domain where they are divergent
    • 批准号:
      22740019
    • 项目类别:
      Grant-in-Aid for Young Scientists (B)
    • 资助金额:
      $1.25万
    • 财政年份:
      2010
    • 负责人:
      ISHIKAWA Hideaki
    • 依托单位:
    Analysis of the CD45-Lyn-mediated signaling pathways in theIL-6-induced myeloma cell proliferation
    • 批准号:
      19591115
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.0万
    • 财政年份:
      2007
    • 负责人:
      ISHIKAWA Hideaki
    • 依托单位:
    国内基金
    海外基金
    早期滋养型肠内营养联合益生菌对重症卒中患者喂养耐受性及TNF-α/IL-6水平的影响研究
    七氟烷通过调控IL-6/FSP1轴抑制心肌铁死亡减轻心肌缺血再灌注损伤的机制研究
    • 批准号:
      JCZRLH202601296
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
    • 依托单位:
    盐酸小檗碱抑制NF-κB/IL-6/STAT3信号通路重塑免疫微环境并增敏肺癌免疫治疗的研究
    • 批准号:
      JCZRLH202600985
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
    • 依托单位:
    双歧杆菌与消退素RvD1协同调控IL-6/STAT3/Notch信号轴介导结肠癌EMT及免疫调节的机制研究
    • 批准号:
      JCZRLH202601410
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
    • 依托单位: